01Model confirmation
Tumor tissue, PDO bright-field and PDO H&E
Source tissue and PDO views establish histological context before treatment experiments.
Sets the histological baseline for treatment comparisonStudy resultsCase study
Renal cancer PDO 2.0: apoptosis & immune response
Source-tissue/PDO histology establishes model context; Annexin V/PI and CD3/CD8 flow compare apoptosis and immune change across treatment conditions.
01Study objective02Model & design03Assays & findings04Decision & next step
Model & sampleRenal cancer PDO 2.0 with source-tissue comparison
ObjectiveCompare tumor apoptosis and immune changes
Study conditionsTargeted, immune and combination conditions configured for the study
AssaysH&E, Annexin V/PI and CD3/CD8 flow cytometry
Study evidenceTRiCBIO RCC PDO 2.0 study data
DeliverablesReceive images, assay results and an analysis summary; the report documents the study design, sample size and statistical methods
STUDY EVIDENCE
Integrated evaluation of model identity, apoptosis and immune change
Tumor tissue–PDO comparison establishes model context, while Annexin V/PI and CD3/CD8 flow cytometry show cell-death and immune changes across treatment conditions.
02Apoptosis
Annexin V/PI distributions across treatments
Flow plots show Annexin V/PI distributions under control, targeted, immune and combination conditions.
Guides replication and additional cell-death endpoint design03Immune flow
CD8-positive cells within the CD3+ subset
Flow plots under the same treatment conditions show changes in CD8-positive cells within the CD3+ subset alongside apoptosis readouts.
Adds an immune dimension to treatment comparison
INTERPRETATION
Apoptosis and immune response
Annexin V/PI and CD3/CD8 flow readouts compare apoptosis and T-cell changes across treatments.
Treatment comparisons are interpreted within the study's sample background, dose, exposure time and controls.
Compare dose and time-course effects, then deepen validation with mechanism endpoints and independent samples.
Related models and services
Choose the right models and services for the next study
Study planning
Build your study from this evidence
Candidate comparison and mechanism studies
Candidates, dosing conditions, controls and sample pathology
Model confirmation, treatment execution, apoptosis and immune flow assays
Study records, flow and histology images, comparative analysis and report
Plan follow-on dose, mechanism and additional-sample studies
Dose, timing, sample context, replication and flow gating
PROJECT DISCUSSION
Discuss a study built around your program
Tell us which model, assay or finding you want to extend. Our scientists will adapt the approach to your candidate, samples and decision point.